Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non Operating Income (2017 - 2024)

Aclaris Therapeutics (ACRS) has 8 years of Other Non Operating Income data on record, last reported at $1.9 million in Q2 2024.

  • For Q2 2024, Other Non Operating Income fell 16.83% year-over-year to $1.9 million; the TTM value through Jun 2024 reached $8.4 million, up 31.29%, while the annual FY2023 figure was $8.5 million, 188.83% up from the prior year.
  • Other Non Operating Income reached $1.9 million in Q2 2024 per ACRS's latest filing, down from $2.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $2.3 million in Q3 2023 and bottomed at -$851000.0 in Q3 2021.
  • Average Other Non Operating Income over 5 years is $763722.2, with a median of $320000.0 recorded in 2020.
  • Peak YoY movement for Other Non Operating Income: plummeted 338.66% in 2021, then skyrocketed 1522.47% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at -$219000.0 in 2020, then skyrocketed by 140.64% to $89000.0 in 2021, then soared by 1522.47% to $1.4 million in 2022, then soared by 51.59% to $2.2 million in 2023, then fell by 14.66% to $1.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $1.9 million in Q2 2024, $2.0 million in Q1 2024, and $2.2 million in Q4 2023.